These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 21942262

  • 1. Effects of varenicline and bupropion on cognitive processes among nicotine-deprived smokers.
    Ashare RL, McKee SA.
    Exp Clin Psychopharmacol; 2012 Feb; 20(1):63-70. PubMed ID: 21942262
    [Abstract] [Full Text] [Related]

  • 2. Nicotine receptor partial agonists for smoking cessation.
    Cahill K, Stead LF, Lancaster T.
    Cochrane Database Syst Rev; 2010 Dec 08; (12):CD006103. PubMed ID: 21154363
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pharmacological interventions for smoking cessation: an overview and network meta-analysis.
    Cahill K, Stevens S, Perera R, Lancaster T.
    Cochrane Database Syst Rev; 2013 May 31; 2013(5):CD009329. PubMed ID: 23728690
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Nicotine receptor partial agonists for smoking cessation.
    Cahill K, Stead LF, Lancaster T.
    Cochrane Database Syst Rev; 2012 Apr 18; (4):CD006103. PubMed ID: 22513936
    [Abstract] [Full Text] [Related]

  • 7. Effects of the alpha4beta2 partial agonist varenicline on brain activity and working memory in abstinent smokers.
    Loughead J, Ray R, Wileyto EP, Ruparel K, Sanborn P, Siegel S, Gur RC, Lerman C.
    Biol Psychiatry; 2010 Apr 15; 67(8):715-21. PubMed ID: 20207347
    [Abstract] [Full Text] [Related]

  • 8. Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal.
    Cinciripini PM, Robinson JD, Karam-Hage M, Minnix JA, Lam C, Versace F, Brown VL, Engelmann JM, Wetter DW.
    JAMA Psychiatry; 2013 May 15; 70(5):522-33. PubMed ID: 23536105
    [Abstract] [Full Text] [Related]

  • 9. Nicotine receptor partial agonists for smoking cessation.
    Cahill K, Stead LF, Lancaster T.
    Cochrane Database Syst Rev; 2008 Jul 16; (3):CD006103. PubMed ID: 18646137
    [Abstract] [Full Text] [Related]

  • 10. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt.
    West R, Baker CL, Cappelleri JC, Bushmakin AG.
    Psychopharmacology (Berl); 2008 Apr 16; 197(3):371-7. PubMed ID: 18084743
    [Abstract] [Full Text] [Related]

  • 11. Smoking cessation efficacy and safety of varenicline, an alpha4beta2 nicotinic receptor partial agonist.
    Tonstad S.
    J Cardiovasc Nurs; 2006 Apr 16; 21(6):433-6. PubMed ID: 17293731
    [Abstract] [Full Text] [Related]

  • 12. Immediate versus delayed quitting and rates of relapse among smokers treated successfully with varenicline, bupropion SR or placebo.
    Gonzales D, Jorenby DE, Brandon TH, Arteaga C, Lee TC.
    Addiction; 2010 Nov 16; 105(11):2002-13. PubMed ID: 20819082
    [Abstract] [Full Text] [Related]

  • 13. Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials.
    King DP, Paciga S, Pickering E, Benowitz NL, Bierut LJ, Conti DV, Kaprio J, Lerman C, Park PW.
    Neuropsychopharmacology; 2012 Feb 16; 37(3):641-50. PubMed ID: 22048466
    [Abstract] [Full Text] [Related]

  • 14. Combination treatment with varenicline and bupropion in an adaptive smoking cessation paradigm.
    Rose JE, Behm FM.
    Am J Psychiatry; 2014 Nov 01; 171(11):1199-205. PubMed ID: 24934962
    [Abstract] [Full Text] [Related]

  • 15. The effects of varenicline on attention and inhibitory control among treatment-seeking smokers.
    Rhodes JD, Hawk LW, Ashare RL, Schlienz NJ, Mahoney MC.
    Psychopharmacology (Berl); 2012 Sep 01; 223(2):131-8. PubMed ID: 22526531
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.
    Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR, Varenicline Phase 3 Study Group.
    JAMA; 2006 Jul 05; 296(1):56-63. PubMed ID: 16820547
    [Abstract] [Full Text] [Related]

  • 17. Varenicline versus bupropion XL for smoking cessation in older adolescents: a randomized, double-blind pilot trial.
    Gray KM, Carpenter MJ, Lewis AL, Klintworth EM, Upadhyaya HP.
    Nicotine Tob Res; 2012 Feb 05; 14(2):234-9. PubMed ID: 21778151
    [Abstract] [Full Text] [Related]

  • 18. Varenicline: a first-line treatment option for smoking cessation.
    Garrison GD, Dugan SE.
    Clin Ther; 2009 Mar 05; 31(3):463-91. PubMed ID: 19393839
    [Abstract] [Full Text] [Related]

  • 19. Varenicline improves mood and cognition during smoking abstinence.
    Patterson F, Jepson C, Strasser AA, Loughead J, Perkins KA, Gur RC, Frey JM, Siegel S, Lerman C.
    Biol Psychiatry; 2009 Jan 15; 65(2):144-9. PubMed ID: 18842256
    [Abstract] [Full Text] [Related]

  • 20. An internet survey of use, opinions and preferences for smoking cessation medications: nicotine, varenicline, and bupropion.
    Etter JF, Schneider NG.
    Nicotine Tob Res; 2013 Jan 15; 15(1):59-68. PubMed ID: 22529220
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.